- Home
- ABL vs ARVN Comparison
ABL vs ARVN Comparison
Compare ABL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- ARVN
- Stock Information
- Founded
- ABL 2004
- ARVN 2015
- Country
- ABL United States
- ARVN United States
- Employees
- ABL N/A
- ARVN N/A
- Industry
- ABL Investment Managers
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- ARVN Health Care
- Exchange
- ABL Nasdaq
- ARVN Nasdaq
- Market Cap
- ABL 640.3M
- ARVN 676.2M
- IPO Year
- ABL N/A
- ARVN 2018
- Fundamental
- Price
- ABL $6.46
- ARVN $10.12
- Analyst Decision
- ABL Strong Buy
- ARVN Buy
- Analyst Count
- ABL 2
- ARVN 23
- Target Price
- ABL $12.00
- ARVN $17.80
- AVG Volume (30 Days)
- ABL 917.9K
- ARVN 2.2M
- Earning Date
- ABL 11-06-2025
- ARVN 11-05-2025
- Dividend Yield
- ABL N/A
- ARVN N/A
- EPS Growth
- ABL N/A
- ARVN N/A
- EPS
- ABL 0.12
- ARVN N/A
- Revenue
- ABL $196,551,131.00
- ARVN $312,300,000.00
- Revenue This Year
- ABL $81.75
- ARVN N/A
- Revenue Next Year
- ABL $20.16
- ARVN N/A
- P/E Ratio
- ABL $54.56
- ARVN N/A
- Revenue Growth
- ABL 91.93
- ARVN 93.86
- 52 Week Low
- ABL $4.60
- ARVN $5.90
- 52 Week High
- ABL $9.61
- ARVN $27.00
- Technical
- Relative Strength Index (RSI)
- ABL 60.07
- ARVN 54.78
- Support Level
- ABL $5.00
- ARVN $9.27
- Resistance Level
- ABL $7.18
- ARVN $11.51
- Average True Range (ATR)
- ABL 0.40
- ARVN 0.49
- MACD
- ABL 0.18
- ARVN 0.03
- Stochastic Oscillator
- ABL 66.28
- ARVN 39.60
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.